Hamish Alan Cameron
Director/Board Member at Artios Pharma Ltd.
Hamish Alan Cameron active positions
Companies | Position | Start | End |
---|---|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | 01/01/2008 | - |
The Royal College of Physicians | Corporate Officer/Principal | - | - |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | - | - |
Career history of Hamish Alan Cameron
Former positions of Hamish Alan Cameron
Companies | Position | Start | End |
---|---|---|---|
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - | 30/12/2020 |
Chairman | - | 30/12/2020 | |
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 31/12/2005 | 31/12/2007 |
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. | Corporate Officer/Principal | - | - |
ASTRAZENECA PLC | Corporate Officer/Principal | - | - |
Faculty of Pharmaceutical Medicine | Director/Board Member | - | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Corporate Officer/Principal | - | - |
░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░ ░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
Training of Hamish Alan Cameron
University of London | Doctorate Degree |
Statistics
International
United Kingdom | 10 |
United States | 3 |
Switzerland | 3 |
Operational
Director/Board Member | 5 |
Chief Executive Officer | 4 |
Corporate Officer/Principal | 4 |
Sectoral
Health Technology | 10 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ASTRAZENECA PLC | Health Technology |
Private companies | 11 |
---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Cell Medica Switzerland AG
Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Health Technology |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology VHsquared Ltd. develops antibody domain products. It operates as a development stage biologics company which develops a portfolio of orally delivered antibody domain products for gastro intestinal health. The company's novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the gastro intestinal mucosal interface harnessing recent technological developments, including analysis of the micro biota and advances in mucosal immunology. VHsquared was founded in 2010 by William Roderick Justin Richards, Janet Rosemary Robinson, James Scott Crowe, and Gordon Dougan and is headquartered in Cambridge, the United Kingdom. | Health Technology |
X2-Pharma GmbH
X2-Pharma GmbH Pharmaceuticals: MajorHealth Technology X2-Pharma GmbH develops pharmaceutical products for the treatment of inflammatory diseases. It is a biopharmaceutical company that offers small molecule pharmaceuticals for the treatment of inflammatory diseases. The company is headquartered in Heidelberg, Germany. | Health Technology |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Faculty of Pharmaceutical Medicine | |
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Hamish Alan Cameron
- Experience